NCT03306329View on ClinicalTrials.gov

DNS-7801 vs. Placebo in Parkinson's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Parkinson's Disease
Interventions
DRUG

DNS-7801 (low-dose)

DNS-7801 (low-dose) tablets administered once daily.

DRUG

DNS-7801 (high dose)

DNS-7801 (high dose) tablets administered once daily.

DRUG

Placebo

Placebo tablets administered once daily

Trial Locations (9)

28204

The Neurological Institute PA, Charlotte

33486

Parkinsons Disease and Movement Disorders Center of Boca Raton, Boca Raton

33613

University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa

48334

Quest Research Institute, Farmington

63110

Washington University, St Louis

80113

Rocky Mountain Movement Disorders Center, Englewood

90806

Collaborative Neuroscience Network, Long Beach

91105

SC3 Research, Pasadena

99202

Premier Clinical Research, Spokane

Sponsors
All Listed Sponsors
lead

Dart NeuroScience, LLC

INDUSTRY

NCT03306329 - DNS-7801 vs. Placebo in Parkinson's Disease | Biotech Hunter | Biotech Hunter